Australian experience of the SH21 flu vaccination program during the COVID-19 vaccine program

Click to increase image sizeClick to decrease image size

Acknowledgments

We appreciate the excellent medical writing and editorial assistance provided by Anja Giese of Otway Pharmaceutical Development and Consulting. Funding for this editorial assistance was provided by Seqirus Pty Ltd, Melbourne, Australia.

Disclosure of potential conflicts of interest

PGVB has received financial support for education delivery, research, or advisory board attendance from Seqirus and Pfizer. A.N has received financial support for education delivery, or advisory board attendance from Seqirus, Sanofi, GSK, MSD and Pfizer. C.R.M reports grants from Sanofi and other support from Seqirus, AstraZeneca Australia, and Janssen, outside of the submitted work. A.T.K, C.C., and J.A. are employees of Seqirus Pty Ltd, Melbourne, Australia.

Additional information

Funding

This work was supported by the Seqirus Pty Ltd, Melbourne, Australia.